Scleroderma Antibody Test · Blood

Systemic sclerosis, commonly called scleroderma, can quietly damage your lungs, kidneys, and heart for years before symptoms become obvious. A single blood test for anti-Scl-70 (anti-topoisomerase I antibody) can identify one of the most aggressive forms of this disease with a specificity above 95%, meaning a positive result almost never occurs in someone who does not have the condition.

What makes this test especially valuable is that scleroderma antibodies can appear in the blood years before a clinical diagnosis. In one study of military service members who later developed systemic sclerosis, autoantibodies were detectable an average of about 7 years before diagnosis, and in some cases up to 27 years earlier. If you or your doctor have any suspicion of scleroderma, this is the test that turns suspicion into actionable knowledge.

What This Test Actually Measures

The Scl-70 antibody test measures whether your immune system is producing antibodies that attack a protein called topoisomerase I, an enzyme your cells use to manage DNA during cell division. These are IgG antibodies (the most common type of long-lasting immune protein), made by specialized immune cells called plasma cells in your lymph nodes, spleen, and bone marrow.

This is not a test that tracks a normal body process like blood sugar or thyroid function. It detects a specific autoimmune mistake: your immune system has learned to attack one of your own proteins. The result is reported as an antibody index (AI), where values above the lab's cutoff are considered positive. What matters most is whether the antibody is present or absent, not the exact number.

How Scl-70 Fits Into the Broader Antibody Picture

Scleroderma is not one disease. It is a family of related conditions, and different autoantibodies mark different subtypes. In a German registry of 863 systemic sclerosis patients, 94.2% had positive ANA (antinuclear antibodies, a general screening test for autoimmune disease). But five specific antibody targets accounted for over 95% of all known scleroderma-associated immune responses: centromere, topoisomerase I (Scl-70), PM-Scl, U1-RNP, and RNA polymerase.

These antibodies are almost never found together in the same person. In that same registry, only 1.6% of patients had two scleroderma-specific antibodies at once. Each antibody defines a distinct clinical pattern with different organ risks, different progression speeds, and different long-term outcomes. Scl-70 marks one of the more serious subtypes.

Lung Disease Risk

The strongest clinical association with a positive Scl-70 result is interstitial lung disease (ILD), a form of scarring in the lungs that progressively reduces your ability to breathe. In the EULAR Scleroderma Trials and Research database of 3,656 patients, antibody status predicted organ involvement more accurately than the traditional classification of "limited" versus "diffuse" skin disease. Scl-70-positive patients had the highest burden of lung fibrosis among all antibody subgroups.

If your Scl-70 is positive, lung monitoring becomes a priority. This typically means regular pulmonary function tests (measuring how much air your lungs can hold and how well they transfer oxygen) and high-resolution CT imaging of the chest. Catching lung involvement early opens the door to treatments like nintedanib and tocilizumab, which have been shown to slow the decline in lung function.

Survival and Overall Prognosis

A meta-analysis pooling data from 36 cohorts and over 26,000 systemic sclerosis patients found that people with anti-topoisomerase I (Scl-70) antibodies had roughly 38% higher mortality compared to other scleroderma patients (pooled hazard ratio of 1.38). By contrast, those with anti-centromere antibodies had about 42% lower mortality (pooled hazard ratio of 0.58). The overall standardized mortality ratio for systemic sclerosis was 3.45, meaning scleroderma patients die at about 3.5 times the rate of the general population.

These survival differences are driven primarily by organ complications, especially lung fibrosis, pulmonary arterial hypertension (high blood pressure in the lung arteries), and cardiac involvement. The EUSTAR database study of 5,860 patients confirmed that pulmonary fibrosis and pulmonary arterial hypertension are the leading scleroderma-related causes of death.

Cancer Associations by Antibody Type

Cancer risk in scleroderma varies dramatically depending on which antibody you carry. In a Johns Hopkins cohort of 2,383 patients followed over 37,686 person-years, those with anti-RNA polymerase III antibodies (a different scleroderma antibody, not Scl-70) had about 2.8 times the cancer rate of the general population within three years of scleroderma onset. Anti-centromere patients actually had a lower cancer rate than the general population over the full follow-up period.

Scl-70 falls between these extremes. It is not one of the high-cancer-risk antibodies, but it does not carry the protective signal that anti-centromere provides. If your result is positive for Scl-70, standard age-appropriate cancer screening is appropriate, but the intensified cancer surveillance recommended for anti-RNA polymerase III patients is not typically necessary.

How Scl-70 Compares to Other Scleroderma Antibodies

Sources: Mierau et al. 2011 (n=863), Walker et al. 2007 (n=3,656), Elhannani et al. 2025 (meta-analysis of 93 studies, n=23,038), Lazzaroni et al. 2021 (n=7,923).

What this means for you: your specific antibody result does not just confirm or deny scleroderma. It tells your doctor which organs to watch most closely, how aggressively to monitor, and which complications are most likely in your case.

Interpreting Your Result

This test is reported as positive or negative, sometimes with a numerical antibody index. There are no "optimal" or "borderline" tiers the way there are for cholesterol or blood sugar. A result above your lab's cutoff is positive. A result below it is negative. The exact number does not reliably track disease activity: a higher titer does not necessarily mean worse disease, and small fluctuations between tests do not carry clear clinical meaning.

In the SCOT trial, researchers found that baseline titers of traditional scleroderma antibodies like Scl-70 did not predict clinical outcomes after intensive treatment. This reinforces that the value of the test is in identifying your disease subtype and organ risk profile, not in tracking a number up or down over time.

A positive result in someone with compatible symptoms (Raynaud's phenomenon, skin tightening, swollen fingers, unexplained lung scarring) is highly diagnostic. A positive result without any symptoms warrants close follow-up, given that antibodies can precede clinical disease by years. A negative result does not rule out scleroderma: about 14% of clinically defined scleroderma patients test negative for all common scleroderma-specific antibodies.

When Results Can Be Misleading

The biggest source of confusion is not a false reading on this specific test but an incomplete panel. Many standard autoantibody panels test only for Scl-70 and anti-centromere, missing other clinically significant scleroderma antibodies like anti-RNA polymerase III, anti-PM/Scl, anti-Th/To, and anti-fibrillarin. A "negative scleroderma antibody" result from a limited panel can create false reassurance. If clinical suspicion remains high, an extended panel through a specialist lab is the right next step.

Immune checkpoint inhibitors (used in cancer treatment) can trigger new autoimmune phenomena and occasionally new autoantibodies, which could complicate interpretation in someone being tested for the first time while on immunotherapy. Broad immunosuppressive medications like high-dose corticosteroids can blunt antibody production over time, potentially lowering detectable levels without eliminating the underlying autoimmune process.

Common chronic medications like statins, metformin, GLP-1 receptor agonists, proton pump inhibitors, and thyroid medications have not been shown to alter scleroderma antibody results. Short-term stressors like illness, exercise, surgery, or meals do not cause meaningful transient swings in autoantibody levels the way they can with inflammatory markers like CRP.

Tracking Over Time

Unlike metabolic biomarkers where serial trending reveals a trajectory, the Scl-70 antibody is primarily a one-time classification tool. Once you know your antibody status, the clinical value comes from monitoring the organs that antibody puts at risk, not from retesting the antibody itself repeatedly.

That said, there are situations where retesting makes sense. If your initial result was borderline or equivocal, repeating the test in 3 to 6 months can clarify your status. If you were tested with a limited panel and remain symptomatic, ordering an extended scleroderma antibody panel is more useful than simply repeating the same test. And if you are on intensive immunosuppressive therapy or have undergone stem cell transplantation, your antibody profile may shift over months to years.

For someone with a confirmed positive Scl-70, the real "trending" happens with organ function tests: pulmonary function every 6 to 12 months, echocardiography for pulmonary hypertension screening, kidney function monitoring, and periodic high-resolution chest CT. These are the numbers that tell you whether your disease is stable, progressing, or responding to treatment.

What to Do With Your Result

If your Scl-70 is positive, the next steps depend on whether you already have a scleroderma diagnosis. If you do, this result helps your rheumatologist prioritize lung surveillance and choose among treatment options. If you do not yet have a diagnosis but have symptoms like Raynaud's, skin changes, or unexplained shortness of breath, a positive Scl-70 strongly supports referral to a rheumatologist experienced in scleroderma, along with baseline pulmonary function testing, chest CT, and echocardiography.

If the result is negative but you have symptoms that suggest scleroderma, request an extended antibody panel that includes anti-centromere, anti-RNA polymerase III, anti-PM/Scl, and ideally anti-Th/To, anti-fibrillarin, and anti-NOR90. A rheumatologist can also evaluate nailfold capillaroscopy (a quick, non-invasive look at the tiny blood vessels in your nail folds) which is one of the best early screening tools for scleroderma.

If the result is negative and you have no symptoms, scleroderma is very unlikely. There is no evidence supporting routine screening for scleroderma antibodies in the general population. This test is most valuable when clinical suspicion already exists.